On the other hand, the LCN2 level does not decrease during the progression of breast cancer, myeloproliferative neoplasms, skin squamous cell carcinoma, gastric carcinoma, esophageal squamous cell carcinoma, or thyroid cancer. Here, LCN2 is linked to myeloproliferative neoplasm.